Physician profile
Harleen Kaur
NPI 1285296038
$1,422.69
in general payments reported to CMS, 2019-2025
22 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.39 · 2022: $61.46 · 2024: $323 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,330.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $211.01 | 2024-2025 | Gocovri |
| Novartis Pharmaceuticals Corporation | $164.74 | 2024-2025 | |
| Abbvie INC. | $157.48 | 2022-2025 | |
| Medtronic, INC. | $145.22 | 2022-2024 | Percept PC Brainsense, Activa PC |
| Ucb, INC. | $122.71 | 2024-2025 | Briviact, Nayzilam |
| Neurelis, INC. | $109.79 | 2025 | Valtoco |
| Argenx US, INC. | $63.54 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Amneal Pharmaceuticals LLC | $54.17 | 2024-2025 | Crexont, Rytary |
| Biogen, INC. | $47.24 | 2025 | Spinraza |
| Neurocrine Biosciences, INC. | $45.19 | 2025 | |
| Genentech USA, INC. | $39.07 | 2025 | Ocrevus Zunovo |
| Tanabe Pharma America, INC. | $33.21 | 2024 | |
| Pfizer INC. | $32.28 | 2025 | |
| Ge Healthcare | $30.39 | 2021 | |
| Emd Serono, INC. | $29.84 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $24.33 | 2025 | |
| Mallinckrodt Hospital Products INC. | $23.31 | 2024 | Acthar |
| Otsuka America Pharmaceutical, INC. | $21.34 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $20.77 | 2025 | Symbravo |
| Lundbeck LLC | $16.86 | 2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $16.70 | 2025 | Ultomiris |
| Revance Therapeutics, INC. | $13.50 | 2024 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harleen Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.